The standard of care for monitoring epithelial ovarian cancer after initial treatment may be evolving, with new research suggesting a more nuanced approach than relying solely on CA-125 blood tests and CT scans. For years, these tools have been central to detecting recurrence, but a growing body of evidence indicates their limitations and potential for unnecessary anxiety and intervention. Rethinking epithelial ovarian cancer surveillance protocols is becoming increasingly important as clinicians seek to improve both patient outcomes and quality of life.
Epithelial ovarian cancer is often diagnosed at a late stage, making it the leading cause of death from gynecologic cancers. The Centers for Disease Control and Prevention estimates that approximately 22,530 women will be diagnosed with ovarian cancer in the United States in 2024. Following initial treatment – typically surgery and chemotherapy – surveillance is crucial to identify any return of the disease. However, determining the optimal frequency and methods of surveillance has been a long-standing challenge.
The Role of CA-125 and CT Scans
CA-125 is a protein often elevated in the blood of women with ovarian cancer. Increases in CA-125 levels can signal a recurrence, prompting further investigation. Similarly, contrast-enhanced CT scans of the abdomen and pelvis are used to visualize the ovaries and surrounding tissues, looking for any signs of new or growing tumors. A study published in 2016 in JAMA Oncology examined the use of these tools in a large cohort of patients. Researchers analyzed data from 2,861 women diagnosed with ovarian cancer at National Comprehensive Cancer Network (NCCN) institutions between 2004 and 2011. The study found that 2,082 women underwent cytoreductive surgery and chemotherapy, and 1,241 met criteria for clinical remission.
Despite their widespread use, both CA-125 and CT scans have limitations. CA-125 levels can be elevated due to benign conditions, leading to false positives and unnecessary procedures. Conversely, some ovarian cancers produce low levels of CA-125, resulting in false negatives. CT scans as well carry the risk of radiation exposure and may not detect small recurrences. Interpreting ambiguous findings on CT scans can lead to anxiety and potentially unnecessary surgical interventions.
Beyond CA-125 and CT: Exploring New Avenues
Researchers are actively investigating alternative and complementary approaches to ovarian cancer surveillance. These include exploring new biomarkers, refining imaging techniques, and incorporating liquid biopsies – analyzing circulating tumor DNA (ctDNA) in the blood. A comprehensive review published in Cancers in 2020 highlights the correlation between CA125 levels and tumor burden, but also acknowledges the need for more sensitive and specific markers.
Liquid biopsies hold particular promise. By detecting ctDNA, clinicians may be able to identify recurrence earlier and more accurately than with CA-125 alone. However, liquid biopsies are not yet widely available and require further validation in large clinical trials. Other areas of research include the use of MRI and PET/CT scans, which may offer improved sensitivity and specificity compared to traditional CT scans.
The Impact of the “Rustin Criteria”
The 2016 JAMA Oncology study also examined the impact of the “Rustin criteria” – a set of guidelines for interpreting CA-125 levels and CT scan findings – on surveillance practices. The study divided patients into two groups: those evaluated before the widespread adoption of the Rustin criteria (pre-Rustin) and those evaluated after (post-Rustin). The findings suggest that the implementation of the Rustin criteria may have influenced the frequency of imaging and the threshold for intervention, though further research is needed to fully understand the impact.
Personalized Surveillance Strategies
The future of ovarian cancer surveillance likely lies in personalized strategies tailored to individual patient risk factors and disease characteristics. Factors such as the stage of the original cancer, the response to initial treatment, and the presence of specific genetic mutations may all influence the optimal surveillance plan. A “one-size-fits-all” approach is increasingly recognized as inadequate.
This shift towards personalized medicine requires a collaborative effort between oncologists, radiologists, and patients. Open communication and shared decision-making are essential to ensure that surveillance strategies align with patient preferences and values. Patients should be fully informed about the benefits and risks of different surveillance options and empowered to participate in their own care.
As research continues to refine our understanding of ovarian cancer recurrence, it’s clear that a more sophisticated and individualized approach to surveillance is needed. While CA-125 and CT scans will likely remain important tools, they should be used in conjunction with other biomarkers and imaging techniques, and interpreted within the context of each patient’s unique clinical profile.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The next major checkpoint in this evolving field will be the release of results from ongoing clinical trials evaluating the efficacy of liquid biopsies and other novel surveillance strategies. Patients and healthcare providers are encouraged to stay informed about these developments and to discuss the latest research findings. Share your thoughts and experiences with ovarian cancer surveillance in the comments below.
Keep reading
